Search

Displaying results 5061 - 5070 of 10000 in total
  1. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity

  2. Drug

    Paclitaxel docosahexaenoic acid

    go.drugbank.com/drugs/DB05297
    Investigational

    It is a type of mitotic inhibitor.

  3. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. … KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.

  4. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.

  5. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.

  6. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

  7. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

  8. Drug

    Amcinonide

    go.drugbank.com/drugs/DB00288
    Approved

    Amcinonide is a corticosteroid.

  9. Drug

    Hydrocortisone aceponate

    go.drugbank.com/drugs/DB14538
    InvestigationalVet approved

  10. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. … Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR.